Allergan subsidiary gives Syndax rights to acute leukemia treatment | Teva seeks FDA approval of migraine drug | AstraZeneca submits lung cancer drug for approval
ADVERTISEMENT
October 18, 2017
Bio SmartBrief
SIGN UP ⋅   FORWARD
Today's Top Story
Allergan subsidiary gives Syndax rights to acute leukemia treatment
Allergan subsidiary Vitae Pharmaceuticals granted Syndax Pharmaceuticals exclusive global rights to menin-MLL fusion oncogene inhibitors to treat patients with acute leukemia who have chromosomal rearrangements in the MLL gene. The deal grants Allergan $5 million upfront plus milestones and royalty fees.
BioCentury (10/17) 
LinkedIn Twitter Facebook Google+ Email
An RFP Planning Guide Just for Oncology Sponsors
Explore key cost drivers for oncology studies, such as: impact of geography, uncovering project management variations, and how timeline impacts cost savings. Download this complimentary eBook from Novella Clinical: RFP Guide to Oncology Clinical Trials.
ADVERTISEMENT
Health Care & Policy
Teva seeks FDA approval of migraine drug
An FDA biologics license application was filed by Teva Pharmaceutical Industries for fremanezumab, a once-monthly subcutaneous injection being developed to prevent migraines.
Seeking Alpha (free registration) (10/17) 
LinkedIn Twitter Facebook Google+ Email
AstraZeneca submits lung cancer drug for approval
The FDA will assess AstraZeneca's Imfinzi, or durvalumab, as a treatment for locally advanced, stage 3, unresectable non-small cell lung cancer that has not progressed following platinum-based chemoradiation.
PharmaPhorum (U.K.) (10/17) 
LinkedIn Twitter Facebook Google+ Email
EMA gives PRIME status to Ignyta's solid tumor drug
The European Medicines Agency accepted into its PRIME priority medicines program Ignyta's entrectinib, which is being developed to treat adult and pediatric patients with NTRK-positive, locally advanced or metastatic solid tumors with disease progression after previous treatment and those with no other acceptable therapeutic options.
Seeking Alpha (free registration) (10/17) 
LinkedIn Twitter Facebook Google+ Email
FDA approves Phase IIb study of MiMedx's osteoarthritis drug
The FDA approved a Phase IIb study of MiMedx's investigational new drug Amniofix for osteoarthritis of the knee. The company anticipates the 318-patient clinical trial to start next quarter.
Reuters (10/17) 
LinkedIn Twitter Facebook Google+ Email
Suven obtains patent from Singapore for neurodegenerative disease treatments
Suven Life Sciences received a Singapore product patent to develop treatments for patients with neurodegenerative diseases such as Parkinson's, schizophrenia, Alzheimer's, Huntington's and attention-deficit/hyperactivity disorder.
The Economic Times (India)/Press Trust of India (10/18) 
LinkedIn Twitter Facebook Google+ Email
7 keys: Put real-world evidence into action
Life sciences organizations need to know how their therapies work in the real world once clinical trials end. And these seven key components to standardizing real-world data and analytics platforms are how they get started. Read the paper, Institutionalizing Real World Evidence.
ADVERTISEMENT
Company & Financial News
Takeda enters liver disease deal with HemoShear
Takeda Pharmaceutical agreed to collaborate with HemoShear Therapeutics to discover, explore and develop targets for the possible treatment of liver diseases, including nonalcoholic steatohepatitis. The deal gives Takeda exclusive access to HemoShear's REVEAL-Tx platform for fatty liver diseases and grants HemoShear undisclosed upfront payments and research funding, plus $470 million in milestone payments and royalties.
BioCentury (10/17) 
LinkedIn Twitter Facebook Google+ Email
Follow-on funding brings in $80M for Abeona
A follow-on funding raised $80 million for Abeona Therapeutics. The company has an ongoing Phase I/II study of its mucopolysaccharidosis IIIA candidate ABO-102 and plans to initiate a late-stage study of EB-101 for the treatment of recessive dystrophic epidermolysis bullosa by next year.
BioCentury (10/17) 
LinkedIn Twitter Facebook Google+ Email
The Latest From BIO ...
Nikon -- Latest from BIO
Access award-winning solutions from Nikon! BIO preferred partner, Nikon, has won the 2017 iF Design Award, a globally recognized award sponsored by iF International Forum Design GmbH since 1953. Access these distinguished solutions!
LinkedIn Twitter Facebook Google+ Email
Learn more about BIO:
Conferences | Join Bio | Media | Issues | Industry
Food & Agriculture
Will gene editing revolutionize food production?
Gene editing -- a practice that lets scientists add or subtract traits without introducing foreign DNA -- could be a key to feeding the world, according to top executives from Monsanto and DowDuPont. "We can do in six months now what used to take us six or seven years," said James Collins Jr., chief operating officer of DowDuPont's agriculture division.
The Wall Street Journal (tiered subscription model) (10/15) 
LinkedIn Twitter Facebook Google+ Email
 
Industrial & Environmental
Researchers create renewable jet fuel from lumber waste
A research team at Washington State University created jet biofuel from lumber waste. The team demonstrated its work with an Alaska Airlines flight from Seattle to Washington, D.C., last November.
Daily Evergreen (Washington State University) (10/16) 
LinkedIn Twitter Facebook Google+ Email
News From BIO
Make meaningful connections at the J.P. Morgan annual health care conference
BIO's newest industry offering: BIO One-on-One Partnering™ during the J.P. Morgan annual health care conference, Jan. 7-11, 2018, is the most cost-effective way to make valuable connections in the biotech and pharma industries without traveling the world. Communicate directly with prospective biotech investors and senior business and scientific management executives attending BIO's portfolio of events, and schedule meetings in BIO's meeting space at the San Francisco Marriott Marquis. BIO is pleased offer complimentary access to BIO One-on-One Partnering™ during JPM to make it easier and more affordable to partner in downtown San Francisco. Sign up today.
LinkedIn Twitter Facebook Google+ Email
Learn more about BIO:
Conferences | Join Bio | Media | Issues | Industry
Press Releases
Post a Press Release
  
  
Make no little plans; they have no magic to stir men's blood. ... Make big plans; aim high in hope and work.
Daniel Burnham,
architect and urban designer
  
  
The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at bio@smartbrief.com.
Sign Up
SmartBrief offers 200+ newsletters
Advertise
Learn more about the SmartBrief audience
Subscriber Tools:
Contact Us:
Advertising  -  Wynn Hansen
P: 202.470.1149
Editor  -  Nicole Brown
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2017 SmartBrief, Inc.®
Privacy policy |  Legal Information